Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Editas Medicine, Inc.
Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.
IPO Date: February 3, 2016
Sector: Healthcare
Industry: Biotech
Market Cap: $230.21M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.72 | 3.36%
Avg Daily Range (30 D): $0.12 | 4.93%
Avg Daily Range (90 D): $0.08 | 4.68%
Institutional Daily Volume
Avg Daily Volume: 1.26M
Avg Daily Volume (30 D): 2.87M
Avg Daily Volume (90 D): 2.13M
Trade Size
Avg Trade Size (Sh.): 108
Avg Trade Size (Sh.) (30 D): 240
Avg Trade Size (Sh.) (90 D): 253
Institutional Trades
Total Inst.Trades: 3,799
Avg Inst. Trade: $2M
Avg Inst. Trade (30 D): $1.39M
Avg Inst. Trade (90 D): $1.09M
Avg Inst. Trade Volume: .1M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $2.79M
Avg Closing Trade (30 D): $1.65M
Avg Closing Trade (90 D): $1.17M
Avg Closing Volume: 160.4K
   
News
Jun 27, 2025 @ 12:15 PM
2 Beaten-Down Stocks to Avoid
Source: Prosper Junior Bakiny
Jun 17, 2025 @ 2:07 PM
Editas Medicine Is Great. Here's Why You Shouldn't...
Source: Dan Victor
Jun 12, 2025 @ 6:01 AM
Editas Medicine Reports Proprietary Targeted Lipid...
Source: Editas Medicine
Mar 6, 2025 @ 6:00 PM
Global Genome Editing Market to Grow Rapidly at a ...
Source: Delveinsight
Feb 21, 2025 @ 6:00 PM
Cell and Gene Therapies in Rare Disorders Market t...
Source: Delveinsight
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-3.04 $-.92 $-.55
Diluted EPS $-3.04 $-.92 $-.55
Revenue $ 35.84M $ 4.66M $ 30.6M
Gross Profit $ $ $
Net Income / Loss $ -251.23M $ -76.09M $ -45.4M
Operating Income / Loss $ -260.33M $ -76.16M $ -46.59M
Cost of Revenue $ $ $
Net Cash Flow $ 69.47M $ 7.15M $ 35.71M
PE Ratio